tbuckley/cabot-search huggingface dataset:
THU0116 Singapore Patients with Rheumatoid Arthritis Have A Higher Incidence of Solid-Organ Malignancies than The General Population: Findings from The TTSH RA Registry
Authors: X.R. Lim, X. Gao, W.L.J. Tan, L.W. Koh, T.Y. Lian, W.Q. See, K.P. Leong, E.T. Koh
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> Patients with rheumatoid arthritis (RA) have been shown to have an increased risk of developing malignancies. This study was undertaken to determine the incidence and patterns of malignancy in RA patients and identify risk factors of malignancy among patients with RA. <h3>Methods</h3> Patients from the TTSH RA Registry were followed up longitudinally and those who developed malignancies from 2001 to 2013 after the onset of RA were identified. Age-standardised rates (ASRs) of various cancers were analyzed and compared with the Singapore Cancer Registry data. Risk factors for developing malignancy, including demographics and disease characteristics at baseline, were analyzed using Chi-squared test and student9s t test. <h3>Results</h3> Of the 1,134 patients in the registry, 28 patients were excluded as they developed malignancy prior to study enrollment. 1,106 patients were included in the final analysis. Of the 1,106 patients, 81 patients developed malignancies at a mean interval of 15.1 (SD 9.7) years after the onset of RA. The mean age of the 81 patients was 65.9 (SD 10.8) years, of which 61 (75.31%) were females and 69 (85.19%) were Chinese. There were 70 (86.4%) with solid-organ tumours and 11 (13.6%) haematological malignancies. The ASR of cancer in RA patients was 310.3 for males and 232.5 for females per 100,000 person-years, compared with 229.3 (95%CI 226.5–232) for males and 218.3 (95%CI 213.8–216.3) for females in the general population. By cancer type, there is an increased risk of lung cancer, lymphoid neoplasms and stomach cancer in RA compared with the general population. The risks factors for developing malignancy (p&lt;0.05) include male gender, non-Indian ethnicity, onset of RA at an older age, untreated RA and higher disease activity. <h3>Conclusions</h3> The incidence of solid-organ malignancies was higher than hematological malignancies, unlike that in the literature. The overall risk of malignancy is higher in RA patients. Chronic inflammation from RA is associated with increased risk of malignancy. <h3>Acknowledgement</h3> This study is supported by the Centre Grant, National Medical Research Council, Ministry of Health, NMRC/CG/017/2013. <h3>Disclosure of Interest</h3> None declared
AB0712 Analysis of Different Manifestations in The Cervical Spine Involvement of Longstanding Ankylosing Spondylitis: Atlantoaxial Ankylosis (AAA) and Atlantoaxial Subluxation (AAS)
Authors: S. Lee, T.-H. Kim, Y. Song, Y.B. Joo, J.-B. Jun
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Atlantoaxial ankylosis (AAA) is another late manifestation of cervical spine involvement in longstanding AS and suggest that higher cervical mSASSS is more related with the development of AAA than atlantoaxial subluxation (AAS). AAA does not cause as much cervical instability as AAS. <h3>Objectives</h3> To analyze radiologic and clinical findings of atlantoaxial ankylosis and atlantoaxial subluxation in ankylosing spondylitis <h3>Methods</h3> A total of 150 AS patients (145 men, 5 women, mean age, 36.8 years) who had AAA (60 men and 2 women, mean age, 60 years) or AAS (85 men and 3 women, mean age, 34 years) were randomly gathered and underwent at least two plain radiographs of lateral cervical spine on flexion. The atlantodental interval more than 3mm was considered as AAS. Loss of atlantodental interval was considered as AAA. The plain radiographs of lateral cervical spine were independently analyzed by two radiologists. Interobserver reliability between reader 1 and 2 in scoring mSASSS in AS was analyzed. We compared the results of mSASSS between AAS and AAA to see if it was related to severity or duration of the disease. <h3>Results</h3> The mean mSASSS of AS patients with AAA and AAS were 40.1 and 16.5 respectively and the mean duration of AS patients with AAA and AAS were 19.3 and 13.7 years each. There was a significantly (p&lt;0.05) higher total mSASSS, especially cervical spine mSASSS, for AS patients with AAA than those with AAS after mSASSS was corrected for age and duration. But, disease duration was not significantly related with the development of AAA compared with that of AAS. <h3>Conclusions</h3> We found that it has incidence as high as AAS and both are similar in that they are late presentation of AS and occur in patient with long duration. We found that AAA is another manifestation of cervical spine involvement in longstanding AS and is related to severity of the AS reflected by higher cervical mSASSS. <h3>References</h3> Martel W. The occipito-atlanto-axial joints in rheumatoid arthritis and ankylosing spondylitis. Am J Roentgenol Radium Ther Nucl Med 1961;86:223–240 Meijers KA, van Voss SF, Francois RJ. Radiological changes in the cervical spine in ankylosing spondylitis. Ann Rheum Dis 1968;27:333–338 Lee HS, Kim TH, Yun HR, Park YW, Jung SS, Bae SC, et al. Radiologic changes of cervical spine in ankylosing spondylitis. Clin Rheumatol 2001;20:262–266 Laiho K, Kauppi M. The cervical spine in patients with ankylosing spondylitis. Clin Exp Rheumatol 2002;20:738 n&gt; <h3>Disclosure of Interest</h3> None declared
Unrelated Donor (UD) Cord Blood (CB) Stem Cell Transplantation (SCT) from a Single CB Unit in Older Adults: Excellent Engraftment and Low Early Mortality with a Preparative Regimen of Melphalan (M), Thiotepa (T), Fludarabine(F), and Rabbit (r) Anti Thymocyte Globulin (ATG)
Authors: Rajneesh Nath, Muthalagu Ramanathan, Jan Cerny, Zheng Zhou, Glen D Raffel, Jayde Bednarik, Neng Yu, Laura J Petrillo-Deluca, Zeina Al-Mansour, Zankar Desai
Journal: Blood (2014)
Abstract 13: Elevated Atmospheric Levels of Environmental Allergens Might be Associated with Decreased Risk of an Immunologic Reaction to an Etiologic Trigger in Kawasaki Disease
Authors: Cedric Manlhiot, Sunita O’Shea, Bailey Bernknopf, Nita Chahal, Brian W McCrindle
Journal: Circulation (2015)

Introduction: There is considerable interest in identifying potential etiologic and/or triggering agents for the severe immune response associated with Kawasaki disease (KD). The presence of environmental allergens might modulate the odds of triggering such a response despite those allergens not being direct etiologic agents. Methods: We queried the Canadian hospital discharge database (Canadian Institute for Health Information) for hospital admissions associated with a discharge diagnosis of KD in 2011 in the Greater Toronto Area. Atmospheric levels of pollens (35 species), spores (24 species) and fungi (27 species) were measured by Aerobiology Research Laboratories (Nepean, Ontario). A number of separate models were tested using theoretical incubation periods of 0, 7, 14 or 21 days. Correlation between KD cases and atmospheric levels of environmental allergens were assessed in linear regression models. Results: n=145 patients with KD were included. The highest levels of environmental allergens were in summer months. Overall atmospheric pollens levels were not associated with the KD cases (total pollen count r=0.04, p=0.54); there was no consistent pattern of association with specific pollens. . However, higher levels of spores were associated with a decreased prevalence of KD for all spore species (r=-0.23, p&lt;0.001). Associations were observed for 6 of 19 specific species detected (p&lt;0.001), including leptosphaeria, ascospores, oospore, coprinus/coprinellus, basidiospores, and uredinales . The same pattern was observed for all fungi species (r=-0.17, p=0.009). Associations were observed for 5 of 26 specific fungal species (p=0.002), including alternaria, cladosporium, epicoccum, fusarium, and fungi imperfecti . There were no discernable patterns regarding a potential incubation period. Conclusions: High levels of environmental allergens, particularly fungus and spores, were associated with lower incidence of KD. These results suggest that environmental allergens, even if they are not etiologic agents for KD, might modulate the threshold necessary for the actual etiologic/triggering agent. Atmospheric levels of environmental allergens might be partly responsible for the KD seasonality patterns observed in Canada.
THU0314 Clinical and Immunological Consequences of Total Glucosides of Paeony Treatment in Sjögren's Syndrome: A Randomized Controlled Trial
Authors: Y. Zhou, L. Jin, F. Kong, H. Zhang, Z. Chen, G. Wang, X. Li, X. Li
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Sjögren9s syndrome (SS) is an autoimmune disease and the treatment of SS remains symptomatic. The total glucosides of paeony (TGP) is the active compound extracted from the roots of Paeonia lactiflora Pall. TGP can reduced production of IFN-γ, IL-6 and IL-12, and inhibited dendritic cells. Recently, TGP had been approved in the treatment of rheumatoid arthritis by China State Food and Drug Administration. However, the therapeutic effects of TGP on SS and the mechanisms behind were largely unknown. <h3>Objectives</h3> To investigate the clinical and immunological consequences of total glucosides of paeony (TGP) treatment in patients with Sjögren9s syndrome (SS). <h3>Methods</h3> Forty-five patients with primary SS participated in a randomized, double-blinded, placebo-controlled clinical trial. Patients were assigned randomly to TGP or placebo group in a ratio of 2:1 and followed up for 24 weeks. Clinical assessment was performed by EULAR Sjögren9s Syndrome Patient Reported Index (ESSPRI), stimulated and unstimulated salivary flow rate, and Schirmer test at week 4, 12, 18 and 24. The proportion of B cells and levels of serum IL-6, TNF-α, IFN-γ and BAFF were measured before and after treatment. This trial was registered on www.chictr.org, with the register number of ChiCTR-TRC-12002325. <h3>Results</h3> ESSPRI in the patients who got 3 to 6 score at baseline was significantly reduced in TGP group at 18- and 24-week changed from (4.81±0.60) to (4.15±1.27) (<i>P</i>=0.012) and (4.20±1.46) (<i>P</i>=0.027). Stimulated salivary flow rate increased at week 24 from (1.80±0.39) to (2.01±0.51) (<i>P</i>=0.031) and unstimulated salivary flow rate increased from (1.30±0.92) to (1.55±0.90) (<i>P</i>=0.011) in TGP group, but the placebo group showed no significant difference. Erythrocyte sedimentation rate (ESR) was decreased significantly compared to the placebo group at 12- and 24-week from (40.9±18.0) to (29.4±12.2) (<i>P</i>=0.003) and (30.4±17.3) (<i>P</i>=0.024). The percentage of naive B cells decreased in TGP group from (77.34±12.20)% to (64.59±15.60)% (<i>P</i>=0.005) while memory B cells increased at week 24 from (21.79±11.97)% to (34.21±15.48)% (<i>P</i>=0.006). The concentrations of TNF-α and IFN-γ decreased in TGP group at week 24 from (32.51±26.67) to (24.22±13.56) (<i>P</i>=0.017) and (10.71±8.94) to (6.55±4.88) (<i>P</i>=0.022), respectively. <h3>Conclusions</h3> TGP appears to improve the glandular secreting function and ameliorate the inflammatory process. <h3>Acknowledgement</h3> We thank the patients who participated in the study and Lansen Pharmaceutical Co. Ltd. (Shenzhen, China) which kindly provided drugs. This work was funded by a grant from the National Nature Science Foundation of China (No. 81373187) and the Clinical Research Special Foundation of Chinese Medical Association (12040730373). <h3>Disclosure of Interest</h3> None declared
Risk Factors of GANCICLOVIR–RELATED Neutropenia After Allogeneic STEM CELL Transplantation: A Retrospective Monocenter Study On 547 Patients
Authors: Geoffroy Venton, Roberto Crocchiolo, Jean El-Cheikh, Sabine Furst, Angela Granata, Claire Oudin, Catherine Faucher, Diane Coso, Reda Bouabdallah, Pierre Berger, Norbert Vey, Patrick Ladaique, Christian Chabannon, Michele Merlin, Didier Blaise
Journal: Blood (2012)
SP0168 How New Treatments in Lupus Are Changing The Landscape
Authors: A. Voskuyl
Journal: Annals of the Rheumatic Diseases (2016)

For decades patients with systemic lupus erythematosus have been been treated with classical immunosuppressive drugs, either as single use or in combination, with or without low-medium- high dose corticosteroids. The ultimate goal of treatment is cure, although low disease activity and preferably remission are the primary goals of treatment, yet. Prevention of lupus flares and reduction of corticosteroids dose are in line with these goals. An overview will be given on the current use (indication, efficacy, side effects) of biologicals (i.e. rituximab, belimumab) in lupus, in particular in daily clinical practice. Also, the following questions will be discussed: Do the use of biologicals add to the former mentioned goals of treatment? What can be expected from the use of biologicals in lupus in the future? Which new treatments, including biologicals, are currently being investigated in clinical trials? <h3>Disclosure of Interest</h3> None declared
Death Associated Protein 5 (DAP5/p97/NAT1) Contributes to Retinoic Acid-Induced Granulocytic Differentiation and Arsenic Trioxide Induced Apotosis through Inhibition of PI3K/Akt/mTOR Pathway in Acute Promyelocytic Leukemia Cells: A Novel Mechanism.
Authors: Bulent Ozpolat, Ugur Akar, Isabel Zorilla-Calancha, Pablo Vivas-Mejia, Gabriel Lopez-Berestein
Journal: Blood (2007)
Pre-Transplant Hypogammaglobulinemia Influences Survival after Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT).
Authors: Ronald Sobecks, Matt Kalaycio, Lisa Rybicki, Josephine Chan, Robert Dean, Karen Sands, Mary Serafin, Jennifer Kosar, Steve Andresen, Brad Pohlman, Edward Copelan, Brian Bolwell
Journal: Blood (2007)
Unrelated Cord Blood Following Haploidentical HSCT with Post-Transplant Cyclophosphamide Improves Results of Alternative Donor Transplant in Thalassemia Major
Authors: Chunfu Li, Yuelin He, Jianyun Liao, Wenfeng Xu, Fuyu Pei, Yuqiong Ren, Wanxia Tan
Journal: Blood (2015)
Outcomes of Cord Blood Transplantation Using Reduced Intensity Conditioning for Chronic Lymphocytic Leukemia: A Retrospective Study on Behalf of Eurocord, SFGM-TC and Cqwp-EBMT
Authors: Erick Xavier, Jérôme Cornillon, Annalisa Ruggeri, Patrice Chevallier, Jan J. Cornelissen, Niels S. Andersen, Natacha Maillard, Stephanie Nguyen-coq, Didier Blaise, Eric Deconinck, Hendrik Veelken, Anne Corby, Anna Huynh, Marta Sonia Gonzalez Perez, Jean-Yves Cahn, Noel Milpied, Mohamad Mohty, Mauricette Michallet, Jean-Henri Bourhis, Thierry de Revel, Christian Berthou, Patrice Ceballos, Pascal Turlure, Irene Donnini, Simona Sica, Regis Peffault de la tour, Eliane Gluckman, Nicolaus Kroeger, Johannes Schetelig, Vanderson Rocha
Journal: Blood (2014)
Spleen Tyrosine Kinase Inhibitor Fostamatinib Blocks B Cell Receptor Signaling and Reduces Viability of BCR Subtype Diffuse Large B Cell Lymphoma
Authors: Yue Zhang, Julie Parmentier, Zhongwu Lai, Greg O'Connor, Melissa Passino, Francoise Powell, Erik Devereaux, Kate Byth
Journal: Blood (2012)
A Shorter Time to First Treatment and Worst Overall survival Is Observed in Cll Patients with Reduced Serum IgM As Evaluated with Novel Serum Immunoassays
Authors: Efstathios Koulieris, Katerina Sarris, Nikolitsa Kafasi, Vassiliki Bartzis, Tatiana Tzenou, Dimitrios Maltezas, Sotirios P. Sachanas, Anna Efthymiou, Katerina Mpitsanis, Ioanna Vardounioti, Maria Dimou, Theodoros P. Vassilakopoulos, Marina Siakantaris, Maria K. Angelopoulou, Panagiotis Tsaftaridis, Despoina Mparmparousis, Charis Matsouka, Gerasimos Pangalis, Panayiotis Panayiotidis, Marie-Christine Kyrtsonis
Journal: Blood (2012)
A Phase 1 Trial of Imatinib Mesylate in Combination with Daunorubicin and Cytarabine for Patients for C-kit Positive Relapsed Acute Myeloid Leukemia (AML).
Authors: Anjali S. Advani, Ronald Sobecks, Mikkael A. Sekeres, Ed Copelan, Jennifer Bates, Barbara Tripp, August Salvado, Matt Kalaycio
Journal: Blood (2007)
OP0257 Rheumatoid Arthritis-Specific Cardiovascular Risk Calculators Are Not Superior To Risk Calculators Established for The General Population: A Validation Analysis in A Cohort of RA Patients from 7 Countries
Authors: C.S. Crowson, S.E. Gabriel, A.G. Semb, P.L. van Riel, G. Karpouzas, P.H. Dessein, C. Hitchon, V. Pascual Ramos, G.D. Kitas
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Cardiovascular disease (CVD) risk calculators developed for the general population do not accurately predict CVD events in patients with rheumatoid arthritis (RA). <h3>Objectives</h3> To externally validate risk calculators recommended for use in patients with RA including the European League Against Rheumatism (EULAR) 1.5 multiplier, the Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis (ERS-RA) and QRISK2. <h3>Methods</h3> Seven RA cohorts from United Kingdom, Norway, Netherlands, United States, South Africa, Canada and Mexico were combined. Data on baseline CVD risk factors, RA characteristics and CVD outcomes (including myocardial infarction, ischemic stroke and cardiovascular death) were collected using standardized definitions. Performance of QRISK2, EULAR multiplier and ERS-RA was compared to other risk calculators (ACC/AHA, Framingham Adult Treatment Panel III [FRS-ATP] and Reynolds Risk Score) using c-statistics and net reclassification index (NRI). <h3>Results</h3> Among 1796 RA patients without prior CVD (mean age: 54.0 [SD: 14.0] years, 74% female), 100 developed CVD events during a mean follow-up of 6.9 years (12430 person-years). Estimated CVD risk by ERS-RA (mean: 8.8%, SD: 9.8%) was comparable to FRS-ATP (mean: 9.1%, SD:8.3%) and Reynolds (mean: 9.2%, SD: 12.2%), but lower than ACC/AHA (mean: 9.8%, SD: 12.1%) and QRISK2 (mean: 15.5%, SD: 13.9%) estimates. Discrimination was not improved for ERS-RA (c-statistic=0.69), QRISK2 or EULAR multiplier applied to FRS-ATP and ACC/AHA (c-statistic=0.72 for all) compared to ACC/AHA and FRS-ATP (c-statistic=0.72 for both). The NRI for ERS-RA were low (-0.8% vs. ACC/AHA and 2.3% vs. FRS-ATP). The NRI for QRISK2 compared ACC/AHA was low (-2.4%). The NRI for QRISK2 compared to FRS-ATP was higher, but not significant (NRI: 25.0%, 95% CI: -9.4–34.7%). The EULAR multiplier only reclassified 6 patients above the 7.5% treatment threshold for the ACC/AHA calculator and 3 patients above the 20% treatment threshold for the FRS-ATP calculator, so the NRI was negligible. <h3>Conclusions</h3> The QRISK2, EULAR multiplier and ERS-RA algorithms did not predict CVD risk more accurately in patients with RA than CVD risk calculators developed for the general population. <h3>Acknowledgement</h3> The ATACC-RA consortium: S Gabriel, C Crowson, E Matteson, G Kitas, K Douglas, A Sandoo, AG Semb, S Rollefstad, E Ikdahl, T Kvien, P Van Riel, E Arts, J Fransen, S Rantapää-Dahlqvist, S Wållberg-Jonsson, L Innala, G Karpouzas, P Sfikakis, E Zampeli, P Dessein, L Tsang, MA Gonzalez-Gay, A Corrales, H El-Gabalawy, C Hitchon, V Pascual Ramos, I Contreras Yáñez, M van de Laar, H Vonkeman, I Meek, E Husni, R Overman, I Colunga, D Galarza <h3>Disclosure of Interest</h3> None declared
SAT0064 Therapy Adherence, Prescribed Medications, Disease Activity and Psychosocial Consequences in Patients with Rheumatoid Arthritis: Table 1
Authors: J.G. Kuipers, M. Koller, F. Zeman, K. Müller, J.U. Rüffer
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Adherence to rheumatoid arthritis (RA) treatment is essential for therapeutic success.Factors contributing to therapy adherence and their consequences are under debate. <h3>Objectives</h3> To investigate the relationship between therapy adherence and disease activity as well as patients9 quality of life. <h3>Methods</h3> The survey included a representative, nationwide sample of German physicians specialized in RA and patients with RA. The physician questionnaire assessed disease activity (DAS28), patients9 adherence to therapy and medical prescriptions. The patient questionnaire assessed quality of life (SF-12), health education literacy (i.e., the understanding and use of medical information, HELP), activities of daily living (MDHAQ), fatigue (EORTC QLQ-FA13) and patients9 listings of their medications. Adherence was assessed with a combined measure of physician rating (1= very adherent, 0 = less adherent) and the match between physicians9 prescriptions and patients9 accounts of their medications (1 = perfect match, 0 = no perfect match). Three groups of patients could be distinguished: high (very adherent according to physician and perfect medication match, n=180), medium (either high physician rated adherence or perfect medication match, n=279), and low (0 in both adherence criteria) (n=205). An ANOVA was used to analyze differences in continuous variables among the three groups. <h3>Results</h3> 671 pairs of patient and physician questionnaires were analyzed. Mean patients9 age (73% female) was 60 years (SD=12). At the time of assessment, 67.2% the patients showed low disease activity (DAS28 &lt;3,2), 28.8% moderate disease activity (DAS28 3,2 to 5,1), and 4.0% high disease activity (DAS28 &gt;5,1). There was no relation between adherence and demographic variables. However, it was related to disease activity, numerous psychosocial variables and the number of prescribed medications (Table 1). <h3>Conclusions</h3> This study showed that patient adherence to therapy was associated with less disease activity and higher levels of quality of life. Adherence was also dependent on the total number of prescribed medications. The effects were consistent across different psychosocial domains. The findings may help to detect patients who are at risk not to comply with treatment and eventually to optimize patient education and counseling. <h3>References</h3> Rauscher V et al.: J Rheumatol. 2015 Jan 15. pii: jrheum.140982. Zwikker HE et al.: 2014 Nov 25;8:1635–45. doi: 10.2147/PPA.S66849. eCollection 2014. Gadallah MA et al.: Am J Med Sci. 2014 Dec 3 <h3>Disclosure of Interest</h3> None declared
AB0219 Prevalence and Risk Factors for Lung Disease in Rheumatoid Arthritis
Authors: L. Lehlou, L. Ichchou
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Lung disease is the most common extra-articular location of Rheumatoid Arthritis (RA). <h3>Objectives</h3> This study aims to evaluate the prevalence and risk factors for lung disease in Rheumatoid Arthritis. <h3>Methods</h3> A cross-sectional study of 72 patients fulfilling RA ACR/EULAR criteria was conducted over one year. Epidemiological data and RA parameters were collected. Pulmonary function tests, chest X-ray and high resolution computed tomography (HRCT) were performed. Data analysis was carried out using the SPSS 20 Software. p&lt;0.05 was considered statistically significant. <h3>Results</h3> Means of age and disease duration were 51.39± 12.40 and 11.76±8.17 years respectively. Smoking was active and passive in 8.3% and 9.7% of cases respectively. RA was seropositive in 70% of cases. Means of DAS28, HAQ, Scharp were 4.59±1.80, 1.19 ±0.96 and 71, 05±43.62 respectively. 58.82% of patients were under Methotrexate, 18.1% under Salazopyrine and 81.9% under prednisone. Only 29.2% were symptomatic on the respiratory level. 12.5% had abnormal physical examination. Chest radiography showed abnormalities in 46% and pulmonary function tests were abnormal in 47% of cases. 55.3% of patients had a lung disease confirmed by HRCT and dominated by interstitial disease (19.4%). RA respiratory functional signs were statistically related to the duration time and positive ACPA. Abnormal HRCT was significantly related to age (p=0.01), activity by DAS 28 (p=0.02) and VS (0.04), severity by RF rate (p=0.04) and HAQ (p=0.01). On multivariate analysis, interstitial disease, rheumatoid nodules, emphysema and pleurisy were respectively associated with smoking, sex, respiratory functional signs and age greater than 40 years. <h3>Conclusions</h3> Respiratory disease affects one in two patients in our RA population. It would be related to age and female gender, but also smoking, activity and severity that we should control. <h3>Disclosure of Interest</h3> None declared